Harnessing immune responses in the tumor microenvironment: all signals needed

Clin Cancer Res. 2013 Nov 15;19(22):6061-3. doi: 10.1158/1078-0432.CCR-13-2424. Epub 2013 Oct 4.

Abstract

An agonist CD40 monoclonal antibody (CP-870,893), in combination with gemcitabine, is well tolerated in patients with advanced pancreatic adenocarcinoma. The combination results in induction of cytokines, B cell activation, and clinical responses. These findings support testing of immunotherapies in combination with other established and targeted therapies.

Publication types

  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Antibodies, Monoclonal / immunology*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • CD40 Antigens / agonists*
  • Carcinoma, Pancreatic Ductal / drug therapy*
  • Female
  • Humans
  • Male
  • Pancreatic Neoplasms / drug therapy*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • CD40 Antigens
  • selicrelumab